These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 14603608

  • 1. [Pain therapy in patients with tumors. According to graduated schedule and hourly plan].
    MMW Fortschr Med; 2003 Oct 02; 145(40):53. PubMed ID: 14603608
    [No Abstract] [Full Text] [Related]

  • 2. [Pain therapy with semisynthetic opioids. Patients have opioid-type side effects more rarely].
    Sohn W.
    MMW Fortschr Med; 2003 Jul 10; 145(27-28):50. PubMed ID: 14587190
    [No Abstract] [Full Text] [Related]

  • 3. Hydromorphone-OROS formulation.
    Goforth HW.
    Expert Opin Pharmacother; 2010 May 10; 11(7):1207-14. PubMed ID: 20402557
    [Abstract] [Full Text] [Related]

  • 4. [Delayed action and rapidly effective in combination. Hydromorphone--already a WHO stage 3 drug].
    MMW Fortschr Med; 2006 May 11; 148(19):47. PubMed ID: 16736708
    [No Abstract] [Full Text] [Related]

  • 5. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM, Shi M, Buckley BJ, Kwarcinski MA.
    Clin Ther; 2006 Jan 11; 28(1):86-98. PubMed ID: 16490582
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK, Bijur PE, Baccelieri A, Gallagher EJ.
    Am J Geriatr Pharmacother; 2009 Feb 11; 7(1):1-10. PubMed ID: 19281935
    [Abstract] [Full Text] [Related]

  • 7. Transitioning a cancer patient from high-dose intravenous hydromorphone therapy to intravenous methadone.
    LeBaron V, Brody J, Lee EM, Hardin C, Snyder L.
    J Pain Palliat Care Pharmacother; 2011 Feb 11; 25(4):356-61. PubMed ID: 22126165
    [No Abstract] [Full Text] [Related]

  • 8. [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study].
    Sittig HB.
    MMW Fortschr Med; 2004 Dec 09; 146(Suppl 3-4):95-8. PubMed ID: 15662898
    [Abstract] [Full Text] [Related]

  • 9. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A, Bozkaya D, Fleischmann J, Dubois D, Sabatowski R, Caro JJ.
    Curr Med Res Opin; 2007 Oct 09; 23(10):2333-45. PubMed ID: 17697453
    [Abstract] [Full Text] [Related]

  • 10. [Pain therapy. Extensive possibilities not adequately utilized].
    MMW Fortschr Med; 2005 May 12; 147(19):60-1. PubMed ID: 15940943
    [No Abstract] [Full Text] [Related]

  • 11. [Observational data in elderly pain patients show that fear of opioid therapy is unfounded].
    Junker U, Figge V.
    MMW Fortschr Med; 2005 Jul 07; 147(27-28):43. PubMed ID: 16041941
    [No Abstract] [Full Text] [Related]

  • 12. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study].
    Junker U, Figge V.
    MMW Fortschr Med; 2005 Oct 06; 147 Suppl 3():91-6. PubMed ID: 16261943
    [Abstract] [Full Text] [Related]

  • 13. [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study].
    Sittig HB.
    MMW Fortschr Med; 2004 Dec 02; 146(49):45. PubMed ID: 15646717
    [No Abstract] [Full Text] [Related]

  • 14. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
    O'Connor AB, Zwemer FL, Hays DP, Feng C.
    Acad Emerg Med; 2009 Jun 02; 16(6):477-87. PubMed ID: 19426295
    [Abstract] [Full Text] [Related]

  • 15. Opioid conversion guidelines for managing adult cancer pain.
    Derby SA.
    Am J Nurs; 1999 Oct 02; 99(10):62-5. PubMed ID: 10542852
    [No Abstract] [Full Text] [Related]

  • 16. Oral hydromorphone extended-release.
    Guay DR.
    Consult Pharm; 2010 Dec 02; 25(12):816-28. PubMed ID: 21172762
    [Abstract] [Full Text] [Related]

  • 17. Secondary adrenal failure and secondary amenorrhoea following hydromorphone treatment.
    Müssig K, Knaus-Dittmann D, Schmidt H, Mörike K, Häring HU.
    Clin Endocrinol (Oxf); 2007 Apr 02; 66(4):604-5. PubMed ID: 17371484
    [No Abstract] [Full Text] [Related]

  • 18. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
    Grosset AB, Roberts MS, Woodson ME, Shi M, Swanton RE, Reder RF, Buckley BJ.
    J Pain Symptom Manage; 2005 Jun 02; 29(6):584-94. PubMed ID: 15963867
    [Abstract] [Full Text] [Related]

  • 19. Exceptionally high narcotic analgesic requirements in a terminally ill cancer patient.
    Lo SL, Coleman RR.
    Clin Pharm; 1986 Oct 02; 5(10):828-32. PubMed ID: 2430752
    [No Abstract] [Full Text] [Related]

  • 20. The metamorphosis of hydromorphone.
    Reisfield GM, Wilson GR.
    J Opioid Manag; 2005 Oct 02; 1(3):139-45. PubMed ID: 17315417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.